Robert E. Lee Trout
GlaxoSmithKline
15 Papers
57 Citations
Robert E. Lee Trout is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Chemistry & Cathepsin K. The author has an hindex of 8, co-authored 15 publications.
Chat about Author
Papers
Systemic Activation of the Transient Receptor Potential Vanilloid Subtype 4 Channel Causes Endothelial Failure and Circulatory Collapse: Part 2
Robert N. Willette,Weike Bao,Sandhya S. Nerurkar,Tian-Li Yue,Chris P. Doe,Gerald Stankus,Gregory H. Turner,Haisong Ju,Heath Thomas,Cindy E. Fishman,Anthony Sulpizio,David J. Behm,Sandra J. Hoffman,Zuojun Lin,Irina M. Lozinskaya,Linda N. Casillas,Min Lin,Robert E. Lee Trout,Bartholomew J. Votta,Kevin S. Thorneloe,Erin S. R. Lashinger,David J. Figueroa,Robert W. Marquis,Xiaoping Xu +23 more
TL;DR: In summary, inappropriate activation of TRPV4 produces acute circulatory collapse associated with endothelial activation/injury and failure of the pulmonary microvascular permeability barrier.
291
Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- And Metallo-β-lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections
Bin Liu,Robert E. Lee Trout,G.-H. Chu,Mcgarry Daniel G,Randy W. Jackson,Jodie Hamrick,Denis M. Daigle,Susan M Cusick,Cecilia Pozzi,F. De Luca,M. Benvenuti,Stefano Mangani,Jean Denis Docquier,William J. Weiss,Daniel C. Pevear,Luigi Xerri,Christopher J. Burns +16 more
TL;DR: Taniborbactam is the first pan-spectrum β-lactamase inhibitor to enter clinical development and restored the activity of β- lactam antibiotics against carbapenem-resistant Pseudomonas aeruginosa and carbapanem- resistant Enterobacteriaceae.
234
VNRX-5133 (Taniborbactam), a broad-spectrum inhibitor of serine- And metallo-β-lactamases, restores activity of cefepime in enterobacterales and Pseudomonas aeruginosa
Jodie Hamrick,Jean Denis Docquier,Tsuyoshi Uehara,Cullen L. Myers,David A. Six,Cassandra L Chatwin,Kaitlyn John,Salvador Vernacchio,Susan M Cusick,Robert E. Lee Trout,Cecilia Pozzi,Filomena De Luca,Manuela Benvenuti,Stefano Mangani,Bin Liu,Randy W. Jackson,Greg Moeck,Luigi Xerri,Christopher J. Burns,Daniel C. Pevear,Denis M. Daigle +20 more
TL;DR: Taniborbactam is a new cyclic boronate BLI that is in clinical development combined with cefepime for the treatment of infections caused by β-lactamase-producing CRE and CRPA, and is the first BLI with direct inhibitory activity against Ambler class A, B, C, and D enzymes.
166
Cyclic ketone inhibitors of the cysteine protease cathepsin K.
Robert W. Marquis,Ru Yu,Jin Zeng,Robert E. Lee Trout,Stephen M. LoCastro,Andrew D. Gribble,Jason Witherington,Ashley E. Fenwick,Benedicte Garnier,Thaddeus A. Tomaszek,David G. Tew,Mark E. Hemling,Chad Quinn,Ward W. Smith,Baoguang Zhao,Michael S. McQueney,Cheryl A. Janson,Karla J. D'Alessio,Daniel F. Veber +18 more
TL;DR: Crystallographic and structure--activity studies on a series of acyclic ketone-based inhibitors of cathepsin K have led to the design and identification of two series of cyclic ket one inhibitors, which were bound in the active site of the enzyme in two alternate directions.
54
Patent
Beta-lactamase inhibitors
Christopher J. Burns,Denis M. Daigle,Bin Liu,Mcgarry Daniel G,Daniel C. Pevear,Robert E. Lee Trout +5 more
- 15 Jan 2009
TL;DR: In this article, compounds and compositions that modulate the activity of beta-lactamases are described and described in terms of their ability to inhibit β-Lactamase activity.
38